London
· Delayed Price · Currency is GBP · Price in SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of GBP 21.22 million. The enterprise value is 11.43 million.
| Market Cap | 21.22M |
| Enterprise Value | 11.43M |
Important Dates
The next estimated earnings date is Friday, February 21, 2025.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +50.76% |
| Shares Change (QoQ) | +36.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 183.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.55 |
| EV / Sales | 5.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.64 |
Financial Position
The company has a current ratio of 6.25, with a Debt / Equity ratio of 0.86.
| Current Ratio | 6.25 |
| Quick Ratio | 6.16 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.48 |
| Interest Coverage | -38.99 |
Financial Efficiency
Return on equity (ROE) is -209.92% and return on invested capital (ROIC) is -70.95%.
| Return on Equity (ROE) | -209.92% |
| Return on Assets (ROA) | -57.08% |
| Return on Capital (ROIC) | -70.95% |
| Revenue Per Employee | 25,208 |
| Profits Per Employee | -262,957 |
| Employee Count | 57 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.64% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -80.64% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 28.86 |
| Average Volume (20 Days) | 3,596 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of GBP 1.99 million and -20.77 million in losses. Loss per share was -0.15.
| Revenue | 1.99M |
| Gross Profit | 1.79M |
| Operating Income | -20.63M |
| Pretax Income | -20.65M |
| Net Income | -20.77M |
| EBITDA | -20.43M |
| EBIT | -20.63M |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 18.39 million in cash and 8.62 million in debt, giving a net cash position of 9.77 million.
| Cash & Cash Equivalents | 18.39M |
| Total Debt | 8.62M |
| Net Cash | 9.77M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.98M |
| Book Value Per Share | 0.05 |
| Working Capital | 17.88M |
Cash Flow
In the last 12 months, operating cash flow was -17.98 million and capital expenditures -8,533, giving a free cash flow of -17.99 million.
| Operating Cash Flow | -17.98M |
| Capital Expenditures | -8,533 |
| Free Cash Flow | -17.99M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 89.96% |
| Operating Margin | -1,036.11% |
| Pretax Margin | -1,036.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.76% |
| Shareholder Yield | -50.76% |
| Earnings Yield | -97.89% |
| FCF Yield | -84.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oncopeptides AB has an Altman Z-Score of 0.55. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.55 |
| Piotroski F-Score | n/a |